LSE:GSKPharmaceuticals
GSK Licenses Linerixibat To Alfasigma And Refocuses Growth Story
GSK has licensed global rights to its late stage liver disease drug linerixibat to Alfasigma in a major transaction.
The deal covers linerixibat for cholestatic pruritus in primary biliary cholangitis, with GSK receiving upfront, milestone and royalty payments.
The agreement comes shortly before an expected FDA decision on linerixibat and allows GSK to reallocate resources across its pipeline.
LSE:GSK is making this move at a time when its share price stands at £20.64, with a return of...